Gesynta Pharma completes NOVA trial enrolment ahead of schedule

Gesynta Pharma has completed enrolment in NOVA, its Phase 2 proof-of-concept trial evaluating vipoglanstat in endometriosis, enrolling 213 patients against an original target of 190 and finishing more than three months ahead of schedule. Topline results are anticipated in the second quarter of 2027, which would inform the design of a subsequent Phase 3 programme.

The randomised, double-blind, placebo-controlled study is running across multiple European sites and is assessing two dose levels of the oral candidate over approximately four menstrual cycles. Primary outcome is reduction in non-menstrual pelvic pain; secondary endpoints cover dysmenorrhea, dyspareunia, opioid rescue medication use, and quality-of-life measures, with exploratory MRI assessment of lesion changes.

The candidate

Vipoglanstat works by selectively inhibiting mPGES-1, an enzyme responsible for the synthesis of prostaglandin E2 (PGE2), which is implicated in the inflammation, pain, and lesion growth associated with endometriosis. The mechanism is notably distinct from the hormonal suppression that underpins established second-line treatments such as GnRH agonists and antagonists, which induce menopause-like side effects, carry treatment-duration restrictions, and compromise fertility.

Gesynta has reported that preclinical studies showed a 70% reduction in endometriotic lesions in an advanced disease model, and that clinical studies to date have demonstrated full target engagement, favourable pharmacokinetics, and no safety signals.

Patric Stenberg, chief executive of Gesynta Pharma, said the non-hormonal profile of vipoglanstat appeared to have contributed directly to the pace of recruitment, "resonating with both investigators and patients." Christian Becker, Professor of Reproductive Sciences and Co-Director of the Oxford Endometriosis CaRe Centre, who serves as international coordinating investigator for NOVA, noted that many patients "continue to experience significant symptoms despite existing treatments," underscoring the demand for new non-hormonal approaches.

Market context

Endometriosis affects an estimated one in ten women of reproductive age globally and has historically been an underserved therapeutic area, with decades of treatment innovation limited largely to pain management, hormonal suppression, and surgery. That picture is beginning to shift. Regulatory interest in the indication has grown, with the US Food and Drug Administration's approval of linzagolix and relugolix-combination products for endometriosis-associated pain in recent years extending the options for GnRH-based suppression while simultaneously highlighting their tolerability limitations.

The non-hormonal space in endometriosis remains relatively uncrowded at late clinical stage, giving Gesynta a plausible differentiation story if vipoglanstat's Phase 2 data hold. A number of academic groups and early-stage companies are pursuing anti-inflammatory and prostaglandin-pathway strategies in women's health more broadly, but few have Phase 2 controlled data in endometriosis in hand. Investors with a focus on women's health have become an increasingly distinct capital pool in European life sciences, and Gesynta notes it is backed by both European life science and US women's health specialist funds.

The speed of enrolment is an encouraging operational signal, though it does not speak to efficacy. Market participants will be focused on the Q2 2027 topline readout, particularly the primary pain endpoint and the safety profile relative to the hormonal class, as the gating criteria for any decision to advance to Phase 3.